samedan logo
 
 
spacer
home > ict > spring 2018 > improving success rates
PUBLICATIONS
International Clinical Trials

Improving Success Rates

Innovative methodologies are paving the way to a better outlook for Alzheimer’s clinical trials. Improvements in understanding of pathophysiological mechanisms, innovative clinical trial design, and better operational oversight are addressing well-documented research challenges associated with this complex, multifaceted disease.

Daunting failure rates – reaching 99.6% – have historically plagued advancement of new treatments and potential cures for the 28-37 million people impacted (1,2). However, new insights are helping investigators address a continuing source of problematic research: patient recruitment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Michael F Murphy’s professional career has spanned 25 years and his positions within the pharma industry emphasise the integration of medical and scientific acumen with operational excellence. He is board-certified in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University, and the Mt Sinai School of Medicine, US. Michael worked with Dr Cutler in articulating this vision for Worldwide Clinical Trials when the company was established as a global CRO in 1995. His supervisory responsibilities as Chief Medical and Scientific Officer at Worldwide are international in scope.
spacer
Dr Michael F Murphy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Zenith Technologies Wins ‘Supplier of the Year’ at Pharma Industry Awards 2018

Zenith Technologies, a world leader in delivering manufacturing software to the life sciences industry, has been named ‘Pharma Supplier of the Year’ at the prestigious 2018 Pharma Industry Awards.
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 
Industry Events

SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019

1-2 April 2019, Holiday Inn Kensington Forum, London

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement